晟德大藥廠股份有限公司（TWO：4123）Center Laboratories, Inc.
晟德大藥廠創立於1959年，早期為一個全劑型藥廠。林榮錦董事長自1998年接手管理晟德後，重新定位晟德的競爭優勢並以內服液劑專業製造核心，透過先進的技術平台架構、專業處方研究以及處方設計分析等能力，研發多元化的液劑系列產品，成功帶領晟德轉型為台灣第一大專業內服液劑藥廠。 2008年晟德水劑產品在台灣市佔率已突破70%，林榮錦董事長再次協助晟德制定差異化的成長策略，不僅優化水劑產品組合並投身精神、...
晟德大藥廠股份有限公司（TWO：4123）Center Laboratories, Inc.'s Basic Information
晟德大藥廠股份有限公司（TWO：4123）Center Laboratories, Inc.'s Competitors
Liconic Instruments
Stelis Biopharma
Bengaluru, Karnataka, India
Novacord
Specialty Sera
OncoSynergy
Stamford, Connecticut, United States
Employee Insights
Employee Function
Employee Location
News
Never miss a headline about 晟德大藥廠股份有限公司（TWO：4123）Center Laboratories, Inc.
Track 晟德大藥廠股份有限公司（TWO：4123）Center Laboratories, Inc.'s latest news, public sentiment and brand reputation in one place. Spot funding, launches, leadership changes and risk signals early, and reach out at exactly the right moment.
- ✓Real-time news & sentiment monitoring
- ✓Funding, launch and hiring signals
- ✓Timely talking points for outreach
OrgChart
Map the buying committee at 晟德大藥廠股份有限公司（TWO：4123）Center Laboratories, Inc.
See who reports to whom at 晟德大藥廠股份有限公司（TWO：4123）Center Laboratories, Inc.. Identify executives, department heads and influencers, then go straight to the right decision makers with verified contact details.
- ✓Reporting lines by department and seniority
- ✓Key decision makers and influencers
- ✓Verified emails and direct dials
Events
Meet 晟德大藥廠股份有限公司（TWO：4123）Center Laboratories, Inc. where they show up
Discover the conferences, exhibitions and webinars 晟德大藥廠股份有限公司（TWO：4123）Center Laboratories, Inc. attends, speaks at or sponsors. Turn every event into a warm conversation with the people who matter.
- ✓Upcoming and past event participation
- ✓Speakers, sponsors and attendees
- ✓Pre-event outreach lists
晟德大藥廠股份有限公司（TWO：4123）Center Laboratories, Inc.'s Top Employees
Find Your Next Customer with Better Data
Get access to over 160 million contacts and companies' information in AroundDeal's B2B database, quickly build highly targeted prospect lists and directly reach the buying committee.